Nervenheilkunde
May 14, 2024
Jörg Daumann, Uwe Herwig
ZUSAMMENFASSUNG Die Anwendung von Psychedelika in der Psychotherapie wirft erhebliche ethische, soziale und klinische Fragen auf. Gesundheitliche Risiken, Spezifika des Informed Consent, medialer Einfluss, die Rolle der Therapeuten, Sicherheitsaspekte und der rechtliche Status sind exemplarische Schlüsselbereiche. Auch in der wissenschaftlichen Evaluation der psychedelikaaugmentierten...
Addiction
July 26, 2012
Daniel Wagner, Benjamin Becker, Philip Koester et al.
54 citations
Abstract Aims It is still unclear if cognitive abnormalities in human 3,4‐methylenedioxymeth‐amphetamine ( MDMA ) users existed before the beginning of use or if other confounders could explain the deficits. The present study was conducted in order to assess the relationship between beginning MDMA use and subsequent cognitive performance and to overcome previous methodological shortcomings....
Dialogues in Clinical Neuroscience
September 30, 2009
Euphrosyne Gouzoulis‐mayfrank, Jörg Daumann
115 citations
Ecstasy (MDMA, 3,4-methylendioxymethamphetamine) and the stimulants methamphetamine (METH, speed) and amphetamine are popular drugs among young people, particularly in the dance scene. When given in high doses both MDMA and the stimulant amphetamines are clearly neurotoxic in laboratory animals. MDMA causes selective and persistent lesions of central serotonergic nerve terminals, whereas...
Journal of Psychopharmacology
March 20, 2009
Jörg Daumann, Daniel Wagner, Karsten Heekeren et al.
62 citations
Deficits in attentional functions belong to the core cognitive symptoms in schizophrenic patients. Alertness is a nonselective attention component that refers to a state of general readiness that improves stimulus processing and response initiation. The main goal of the present study was to investigate cerebral correlates of alertness in the human 5HT(2A) agonist and N-methyl-D-aspartic acid...
Psychopharmacology
November 2008
Jörg Daumann, Karsten Heekeren, Anna Neukirch et al.
Attentional deficits are common symptoms in schizophrenia. Recent evidence suggests that schizophrenic patients show abnormalities in spatial orienting of attention, particularly a deficit of inhibition of return (IOR). IOR is mostly thought to reflect an automatic, inhibitory mechanism protecting the organism from redirecting attention to previously scanned, insignificant locations....
Psychopharmacology
May 16, 2008
Karsten Heekeren, Jörg Daumann, Anna Neukirch et al.
158 citations
RATIONALE: Many studies have reported deficits of mismatch negativity (MMN) in schizophrenic patients. Pharmacological challenges with hallucinogens in healthy humans are used as models for psychotic states. Previous studies reported a significant reduction of MMN after ketamine (N-methyl-D-aspartate acid [NMDA] antagonist model) but not after psilocybin (5HT2A agonist model). OBJECTIVES: The...
Journal of Psychopharmacology
May 1, 2007
Karsten Heekeren, Anna Neukirch, Jörg Daumann et al.
49 citations
Patients with schizophrenia exhibit diminished prepuLse inhibition (PPI) of the acoustic startle reflex and deficits in the attentional moduLation of PPI. Pharmacological challenges with hallucinogens are used as models for psychosis in both humans and animals. RemarkabLy, in contrast to the findings in schizophrenic patients and in animal hallucinogen modeLs of psychosis, previous studies with...
Journal of Psychopharmacology
March 1, 2006
Euphrosyne Gouzoulis‐mayfrank, Jörg Daumann
179 citations
The popular dance drug ecstasy (3,4-methylenedioxymethamphetamine -- MDMA) is neurotoxic upon central serotonergic neurons in laboratory animals and possibly also in humans. In recent years, several studies reported alterations of serotonergic transmission and neuropsychiatric abnormalities in ecstasy users which might be related to MDMA-induced neurotoxic brain damage. To date, the most...
Journal of psychopharmacology (Oxford, England)
March 2006
Jörg Daumann, Bianca Till, Thomas Fischermann et al.
Numerous animal studies have been able to demonstrate neurotoxic damage to central serotonergic systems after exposure to 3,4-methylenedioxymethamphetamine (MDMA, ecstasy). It has been suggested that a high loudness dependence of auditory evoked potentials (LDAEP) and, particularly, of the tangential N1/P2 source activity is associated with a low functioning of serotonergic activity. Therefore,...
Addiction
February 27, 2006
Euphrosyne Gouzoulis‐mayfrank, Jörg Daumann
189 citations
ABSTRACT Background The popular dance drug ecstasy (3,4‐methylenedioxymethamphetamine: MDMA and some analogues) causes selective and persistent neurotoxic damage of central serotonergic neurones in laboratory animals. Serotonin plays a role in numerous functional systems in the central nervous system (CNS). Consequently, various abnormalities including psychiatric, vegetative, neuroendocrine...
Psychopharmacology
May 2004
Karsten Heekeren, Jörg Daumann, Mark A Geyer et al.
3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) is neurotoxic upon central serotonin systems in experimental animals and probably also in humans. Serotonin is involved in the habituation, sensitization and prepulse inhibition (PPI) of the startle reflex. To study the plasticity of startle reflex in currently abstinent MDMA users. Electromyographic responses to acoustic startle stimuli (pulse...
Neuroreport
October 1, 2003
Jörg Daumann, Ralph Schnitker, Jürgen Weidemann et al.
46 citations
Poor cognitive performance in ecstasy (3,4-methylenedioxymethamphetamine; MDMA) users has been related to the well-recognized neurotoxic effects of the drug upon central serotonergic and possibly also dopaminergic systems. However, concomitant use of other drugs has been a critical confound in most investigations. In this study we used an n-back task and fMRI to investigate working memory...
Human Psychopharmacology Clinical and Experimental
December 1, 2001
Jörg Daumann, Susanna Pelz, Stefanie Becker et al.
77 citations
Abstract The popular recreational drug Ecstasy (3,4‐methylenedioxymethamphetamine, or MDMA, and related congeners) is neurotoxic upon central serotonergic systems in animal studies. So far, the most convincing evidence for neurotoxicity‐related functional deficits in humans derives from neurocognitive studies demonstrating dose‐related memory problems in Ecstasy users. The aim of the current...